dopamine agonist increases risk taking but blunts reward-related brain activity多巴胺受体激动剂增加冒险但减弱犒赏的大脑活动.pdfVIP

Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity 1,2 ¨ 1 1,3 1,4 ¨ 1,5 Jordi Riba , Ulrike M. Kramer , Marcus Heldmann , Sylvia Richter , Thomas F. Munte * ´ ´ 1 Department of Neuropsychology, University of Magdeburg, Magdeburg, Germany, 2 Departament de Farmacologia i Terapeutica, Centre d’Investigacio del Medicament, ´ ` Institut de Recerca, Servei de Farmacologia Clınica, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain, 3 Department of Neurology II, University of Magdeburg, Magdeburg, Germany, 4 Department of Neurochemistry and Molecular Biology, Leibniz Institute for Neurobiology, Magdeburg, Germany, 5 Center for Behavioral Brain Sciences, Magdeburg, Germany Abstract The use of D2/D3 dopaminergic agonists in Parkinson’s disease (PD) may lead to pathological gambling. In a placebo- controlled double-blind study in healthy volunteers, we observed riskier choices in a lottery task after administration of the D3 receptor-preferring agonist pramipexole thus mimicking risk-taking behavior in PD. Moreover, we demonstrate decreased activation in the rostral basal ganglia and midbrain, key structures of the reward system, following unexpected high gains and therefore propose that pathological gambling in PD results from the need to seek higher rewar